MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

34.77 2.72

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

34.36

Max

34.81

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+57.74% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	941M 2.6B
Ankstesnė atidarymo kaina	32.05
Ankstesnė uždarymo kaina	34.77

Naujienos nuotaikos

By Acuity

100%

336 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-19 23:48; UTC

Svarbiausios naujienos

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

2026-04-19 23:36; UTC

Svarbiausios naujienos

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

2026-04-19 22:47; UTC

Svarbiausios naujienos

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

2026-04-19 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026-04-19 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026-04-19 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

2026-04-19 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-04-19 23:38; UTC

Svarbiausios naujienos

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

2026-04-19 23:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

2026-04-19 23:12; UTC

Svarbiausios naujienos

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

2026-04-19 23:10; UTC

Svarbiausios naujienos

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

2026-04-19 23:09; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

2026-04-19 23:08; UTC

Svarbiausios naujienos

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

2026-04-19 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

2026-04-19 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

2026-04-19 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

2026-04-19 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

2026-04-19 20:03; UTC

Svarbiausios naujienos

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

2026-04-19 20:03; UTC

Svarbiausios naujienos

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

2026-04-19 20:03; UTC

Svarbiausios naujienos

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

2026-04-19 20:03; UTC

Svarbiausios naujienos

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

2026-04-18 01:00; UTC

Svarbiausios naujienos

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

2026-04-17 22:58; UTC

Uždarbis

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026-04-17 21:32; UTC

Rinkos pokalbiai

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Moody's Downgrades Belgium to A1 -- Market Talk

2026-04-17 20:52; UTC

Uždarbis

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026-04-17 20:50; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-04-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-17 20:29; UTC

Uždarbis

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

57.74% į viršų

12 mėnesių prognozė

Vidutinis 54.5 USD 57.74%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.